Willeke M C van Roon-Mom (Willeke Van Roon-Mom, Willeke van Roon-Mom, Willeke van Roon)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 24

Top Topics

Mesenchymal Stem Cells

Sentinel Lymph Node

Clinical Practice

Top Venues

Nucleic acid therapeutics

RNA (New York, N.Y.)

Stem cell reviews and reports

EMBO molecular medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Willeke M C van Roon-Mom, Chantal Ferguson, Annemieke M Aartsma-Rus
From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis. Nucleic acid therapeutics 33 (4) (2023)
Ronald A M Buijsen, Michel Hu, Maria Sáez-González, Sofia Notopoulou, Eleni Mina, Winette Koning, Sarah L Gardiner, Linda M van der Graaf, Elena Daoutsali, Barry A Pepers, Hailiang Mei, Vera van Dis, Jean-Philippe Frimat, Arn M J M van den Maagdenberg, Spyros Petrakis, Willeke M C van Roon-Mom
Spinocerebellar Ataxia Type 1 Characteristics in Patient-Derived Fibroblast and iPSC-Derived Neuronal Cultures. Movement disorders : official journal of the Movement Disorder Society (2023)
Annemieke M Aartsma-Rus, Willeke M C van Roon-Mom, Marlen C Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, Holm Graessner
Development of tailored splice switching oligonucleotides for progressive brain disorders in Europe: development, regulation and implementation considerations. RNA (New York, N.Y.) (2023)
Jasper Ouwerkerk, Stephanie Feleus, Kasper F van der Zwaan, Yunlei Li, Marco Roos, Willeke M C van Roon-Mom, Susanne T de Bot, Katherine J Wolstencroft, Eleni Mina
Machine learning in Huntington's disease: exploring the Enroll-HD dataset for prognosis and driving capability prediction. Orphanet journal of rare diseases 18 (1) (2023)
Annemieke M Aartsma-Rus, Willeke M C van Roon-Mom, Marlen C Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, Holm Graessner
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA (New York, N.Y.) 29 (4) (2023)
Annemieke M Aartsma-Rus, Willeke M C van Roon-Mom, Marlen C Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, Holm Graessner
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA (New York, N.Y.) 29 (4) (2023)
Annemieke M Aartsma-Rus, Willeke M C van Roon-Mom, Marlen C Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, Holm Graessner
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA (New York, N.Y.) 29 (4) (2023)
Laurie M C Kerkhof, Bart P C Van De Warrenburg, Willeke M C van Roon-Mom, Ronald A M Buijsen
Therapeutic Strategies for Spinocerebellar Ataxia Type 1. Biomolecules 13 (5) (2023)
Annemieke M Aartsma-Rus, Willeke M C van Roon-Mom, Marlen C Lauffer, Christine Siezen, Britt Duijndam, Tineke Coenen-de Roo, Rebecca Schüle, Matthis Synofzik, Holm Graessner
Development of tailored splice-switching oligonucleotides for progressive brain disorders in Europe: development, regulation, and implementation considerations. RNA (New York, N.Y.) 29 (4) (2023)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Annemieke M Aartsma-Rus, Alejandro Garanto, Willeke M C van Roon-Mom, Erin M McConnell, Victoria Suslovitch, Winston X Yan, Jonathan K Watts, Timothy W Yu
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Annemieke M Aartsma-Rus, Alejandro Garanto, Willeke M C van Roon-Mom, Erin M McConnell, Victoria Suslovitch, Winston X Yan, Jonathan K Watts, Timothy W Yu
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Annemieke M Aartsma-Rus, Alejandro Garanto, Willeke M C van Roon-Mom, Erin M McConnell, Victoria Suslovitch, Winston X Yan, Jonathan K Watts, Timothy W Yu
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Annemieke M Aartsma-Rus, Alejandro Garanto, Willeke M C van Roon-Mom, Erin M McConnell, Victoria Suslovitch, Winston X Yan, Jonathan K Watts, Timothy W Yu
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic acid therapeutics (2022)
Annemieke M Aartsma-Rus, Alejandro Garanto, Willeke M C van Roon-Mom, Erin M McConnell, Victoria Suslovitch, Winston X Yan, Jonathan K Watts, Timothy W Yu
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Annemieke M Aartsma-Rus, Alejandro Garanto, Willeke M C van Roon-Mom, Erin M McConnell, Victoria Suslovitch, Winston X Yan, Jonathan K Watts, Timothy W Yu
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Annemieke M Aartsma-Rus, Alejandro Garanto, Willeke M C van Roon-Mom, Erin M McConnell, Victoria Suslovitch, Winston X Yan, Jonathan K Watts, Timothy W Yu
Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics (2022)
Aurelie T Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke M C van Roon-Mom, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza, Patrik Andersson
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic acid therapeutics 33 (1) (2022)
Suzan M Hammond, Annemieke M Aartsma-Rus, Sandra Alves, Sven Even F Borgos, Ronald A M Buijsen, Rob W J Collin, Giuseppina Covello, Michela Alessandra Denti, Lourdes Ruiz Desviat, Lucía Echevarría, Camilla Foged, Gisela Gaina, Alejandro Garanto, Aurelie T Goyenvalle, Magdalena Guzowska, Irina Kholodnyuk, David R Jones, Sabine Krause, Taavi Lehto, Marisol Montolio, Willeke M C van Roon-Mom, Virginia Arechavala-Gomeza
Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO molecular medicine 13 (4) (2021)
Marina P Hommersom, Ronald A M Buijsen, Willeke M C van Roon-Mom, Bart P C Van De Warrenburg, Hans van Bokhoven
Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias. Stem cell reviews and reports (2021)